Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-0.93% $0.739
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 78.59 mill |
EPS: | -1.200 |
P/E: | -0.620 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 106.40 mill |
Avg Daily Volume: | 2.96 mill |
RATING 2024-04-23 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.620 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.620 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.552 (-174.80%) $-1.291 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 0.419 - 1.059 ( +/- 43.33%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Hawryluk Matthew | Buy | 35 000 | Common Stock |
2024-02-01 | Hawryluk Matthew | Buy | 180 000 | Stock Option (Right to Buy) |
2024-02-01 | Jones Erin | Buy | 40 000 | Common Stock |
2024-02-01 | Jones Erin | Buy | 235 000 | Stock Option (Right to Buy) |
2024-02-01 | Economides Vassiliki | Buy | 35 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 5 929 842 | Sell: 139 571 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.739 (-0.93% ) |
Volume | 2.41 mill |
Avg. Vol. | 2.96 mill |
% of Avg. Vol | 81.30 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.22 | N/A | Active |
---|
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.